<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460263</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01</org_study_id>
    <nct_id>NCT02460263</nct_id>
  </id_info>
  <brief_title>The EvAluation of TaBlo In-CLinic and In-HOme</brief_title>
  <acronym>TABLO</acronym>
  <official_title>A Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the Tablo Hemodialysis System In-Center and In-Home by Subjects With End Stage Renal Disease (ESRD) Who Are on Stable Dialysis Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outset Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outset Medical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Tablo Hemodialysis System when used In-Center by
      trained individuals and In-Home by trained Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery of a standardized weekly Kt/V of greater than or equal to 2.1</measure>
    <time_frame>weekly for 8 weeks per treatment period for up to 19 weeks</time_frame>
    <description>weekly pre dialysis BUN and post dialysis BUN will be taken to calculate Kt/V</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>In-Center</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Staff administered treatments in-center using the device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>In-Home</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient administered treatments in-home using the device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tablo Hemodialysis System</intervention_name>
    <arm_group_label>In-Center</arm_group_label>
    <arm_group_label>In-Home</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has end stage renal disease (ESRD) adequately treated by maintenance dialysis
             achieving a Kt/V â‰¥ 1.2 and has been deemed stable for at least three months by his/her
             treating nephrologist.

          -  Subject has a well-functioning and stable vascular access that allows a blood flow of
             at least 300 ml/min.

        Exclusion Criteria:

          -  Life expectancy less than 12 months from first study procedure.

          -  Subject has had a recent major cardiovascular adverse event within the last 3 months.

          -  Subject has New York Class III or IV Congestive Heart Failure, or ejection fraction
             less than 30%.

          -  Subject with fluid overload due to intractable ascites secondary to liver cirrhosis.

          -  Subject has uncontrolled blood pressure.

          -  Subject is intolerant to heparin.

          -  Subject is seroreactive for Hepatitis B Surface Antigen.

          -  Subject has an active, life-threatening, rheumatologic disease.

          -  Subject has a history of adverse reactions to dialyzer membrane material.

          -  Subject is expected to receive an organ transplant during the course of the study.

          -  Subject has a life-threatening malignancy actively receiving treatment that would
             prevent successful completion of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoff Block, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Satellite Healthcare</name>
      <address>
        <city>Menlo Park</city>
        <state>California</state>
        <zip>95126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

